Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Elevance Health Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in millions

	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Medical claims payable	17,155)	16,812)	15,746)	15,346)	15,204)	16,459)	16,111)	16,176)	16,165)	15,728)	15,596)	15,242)	15,127)	14,713)	13,518)	13,562)	13,076)	12,347)	11,359)	10,252)	9,878)	9,902)
Other policyholder liabilities	3,540)	3,796)	4,204)	4,402)	4,939)	5,298)	5,600)	5,681)	5,954)	6,098)	5,933)	5,482)	5,577)	5,396)	5,521)	5,201)	5,285)	5,075)	4,590)	3,804)	3,586)	3,252)
Unearned income	1,561)	1,640)	1,508)	1,793)	1,481)	1,474)	1,402)	4,332)	4,458)	4,394)	1,112)	3,702)	971)	1,210)	1,153)	954)	1,081)	1,139)	1,259)	961)	946)	947)
Accounts payable and accrued expenses	7,278)	7,131)	6,927)	6,255)	5,760)	5,658)	6,910)	5,983)	5,033)	4,873)	5,607)	4,963)	5,850)	5,493)	4,970)	5,960)	5,598)	5,329)	5,493)	5,550)	5,257)	5,058)
Short-term borrowings	360)	250)	365)	360)	225)	1,575)	225)	—)	265)	265)	265)	265)	175)	275)	275)	175)	175)	—)	—)	150)	—)	1,075)
Current portion of long-term debt	1,648)	1,643)	1,649)	2,100)	2,900)	2,900)	1,649)	799)	—)	—)	1,500)	2,249)	2,248)	3,097)	1,599)	849)	849)	700)	700)	1,599)	1,603)	1,603)
Other current liabilities	12,292)	11,426)	10,029)	11,614)	11,139)	10,970)	9,894)	10,366)	9,696)	10,531)	9,683)	9,384)	9,360)	9,549)	7,849)	8,461)	7,730)	10,159)	6,052)	6,245)	7,252)	5,202)
Liabilities held for sale	—)	—)	153)	163)	165)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Current liabilities	43,834)	42,698)	40,581)	42,033)	41,813)	44,334)	41,791)	43,337)	41,571)	41,889)	39,696)	41,287)	39,308)	39,733)	34,885)	35,162)	33,794)	34,749)	29,453)	28,561)	28,522)	27,039)
Long-term debt, less current portion	28,178)	28,110)	29,218)	24,688)	24,561)	21,976)	23,246)	24,045)	24,859)	25,201)	22,349)	21,258)	21,165)	19,883)	21,157)	21,761)	22,217)	22,534)	19,335)	19,094)	19,873)	19,005)
Reserves for future policy benefits	163)	174)	190)	248)	295)	765)	778)	807)	797)	811)	737)	825)	822)	811)	802)	788)	774)	776)	794)	784)	776)	754)
Deferred tax liabilities, net	2,008)	2,121)	2,148)	2,092)	2,037)	2,201)	1,970)	1,779)	1,852)	2,029)	2,034)	1,825)	2,021)	2,349)	2,805)	2,629)	2,397)	1,961)	2,019)	2,375)	2,497)	2,213)
Other noncurrent liabilities	3,904)	3,994)	3,326)	3,593)	1,985)	1,908)	1,738)	1,971)	1,777)	1,650)	1,562)	1,788)	1,694)	1,679)	1,683)	1,912)	1,869)	1,745)	1,815)	1,839)	1,853)	1,695)
Noncurrent liabilities	34,253)	34,399)	34,882)	30,621)	28,878)	26,850)	27,732)	28,602)	29,285)	29,691)	26,682)	25,696)	25,702)	24,722)	26,447)	27,090)	27,257)	27,016)	23,963)	24,092)	24,999)	23,667)
Total liabilities	78,087)	77,097)	75,463)	72,654)	70,691)	71,184)	69,523)	71,939)	70,856)	71,580)	66,378)	66,983)	65,010)	64,455)	61,332)	62,252)	61,051)	61,765)	53,416)	52,653)	53,521)	50,706)
Preferred stock, without par value; shares issued and outstanding: none	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Common stock, par value $0.01	2)	2)	2)	2)	2)	2)	2)	2)	2)	2)	2)	2)	2)	2)	2)	2)	2)	2)	3)	3)	3)	3)
Additional paid-in capital	8,931)	8,866)	8,911)	9,105)	9,001)	8,883)	8,868)	8,830)	8,761)	8,697)	9,084)	9,169)	9,134)	9,151)	9,148)	9,138)	9,109)	9,253)	9,244)	9,352)	9,360)	9,338)
Retained earnings	35,549)	34,546)	33,549)	35,157)	34,575)	33,088)	31,749)	32,103)	31,608)	30,707)	29,724)	29,604)	28,825)	28,058)	27,088)	26,700)	25,874)	24,793)	23,802)	24,678)	25,346)	23,360)
Accumulated other comprehensive income (loss)	(760)	(911)	(1,147)	(489)	(1,387)	(1,365)	(1,313)	(2,512)	(2,166)	(2,050)	(2,503)	(2,784)	(2,149)	(1,236)	(178)	(103)	(17)	(195)	150)	(112)	(254)	(1,008)
Shareholders’ equity	43,722)	42,503)	41,315)	43,775)	42,191)	40,608)	39,306)	38,423)	38,205)	37,356)	36,307)	35,991)	35,812)	35,975)	36,060)	35,737)	34,968)	33,853)	33,199)	33,921)	34,455)	31,693)
Noncontrolling interests	129)	117)	111)	104)	106)	102)	99)	116)	107)	104)	87)	52)	55)	56)	68)	71)	78)	65)	—)	—)	—)	—)
Total equity	43,851)	42,620)	41,426)	43,879)	42,297)	40,710)	39,405)	38,539)	38,312)	37,460)	36,394)	36,043)	35,867)	36,031)	36,128)	35,808)	35,046)	33,918)	33,199)	33,921)	34,455)	31,693)
Total liabilities and equity	121,938)	119,717)	116,889)	116,533)	112,988)	111,894)	108,928)	110,478)	109,168)	109,040)	102,772)	103,026)	100,877)	100,486)	97,460)	98,060)	96,097)	95,683)	86,615)	86,574)	87,976)	82,399)

Medical Claims Payable: There is a generally upward trend in medical claims payable from March 2020 to June 2025, increasing from 9,902 million USD to 17,155 million USD, with some fluctuations noted particularly in the second half of 2024.
Other Policyholder Liabilities: Other policyholder liabilities peaked around late 2021 and early 2022 but overall show a declining trend from the high of 5,521 million USD at the end of 2021 to 3,540 million USD by mid-2025.
Unearned Income: Unearned income presents volatility with sharp spikes notably in September 2022 and June 2023, reaching upwards of 4,458 million USD, contrasting with lower values in other quarters. It suggests episodic increases followed by reductions.
Accounts Payable and Accrued Expenses: This item exhibits gradual growth over the period, rising from about 5,058 million USD in early 2020 to 7,278 million USD by mid-2025, although some quarters saw minor decreases.
Short-term Borrowings: Short-term borrowings display inconsistent patterns with some missing data and sporadic fluctuations, generally maintaining relatively low values compared to other liabilities, with a notable peak around mid-2024.
Current Portion of Long-term Debt: This liability fluctuated significantly, with a dramatic decline at the end of 2020 followed by periods of increase and decrease, peaking at 2,900 million USD in mid-2024 and then decreasing again by mid-2025.
Other Current Liabilities: Other current liabilities generally increased from 5,202 million USD in March 2020 to over 12,000 million USD by mid-2025, with some intermittent decreases, indicating growth in current obligations.
Liabilities Held for Sale: Data for liabilities held for sale is mostly absent until early 2025, when small amounts around 150-165 million USD are recorded, suggesting new or discontinued liabilities appearing near that period.
Current Liabilities: Current liabilities increased steadily from 27,039 million USD in March 2020 to a peak near 44,334 million USD in late 2024, with slight declines afterwards indicating a peak in short-term obligations.
Long-Term Debt, Less Current Portion: Long-term debt values fluctuate but overall trend downward from 22,534 million USD in March 2021 to around 28,178 million USD by mid-2025, reflecting borrowing and repayments dynamics.
Reserves for Future Policy Benefits: These reserves remain relatively stable but decreased significantly from 802 million USD toward the end of 2021 to 163 million USD by mid-2025, possibly indicating changing policy liabilities or reserve practices.
Deferred Tax Liabilities, Net: Deferred tax liabilities fluctuate moderately with no persistent trend, oscillating between about 1,779 million USD and 2,629 million USD throughout the period.
Other Noncurrent Liabilities: Other noncurrent liabilities show steady growth until late 2023, after which there is a sharp increase starting in early 2024, reaching nearly 4,000 million USD by mid-2025.
Noncurrent Liabilities: Noncurrent liabilities overall increased from approximately 23,667 million USD in early 2020 to a peak above 34,000 million USD by late 2024, indicative of rising long-term financial obligations.
Total Liabilities: Total liabilities rose steadily from 50,706 million USD in March 2020 to 78,087 million USD by mid-2025, reflecting ongoing growth in both current and noncurrent liabilities.
Common Stock: Common stock remained stable at a nominal value of 2-3 million USD, indicating no significant changes in par value or shares issued during the period.
Additional Paid-in Capital: This component declined slightly from over 9,300 million USD in early 2020 to under 8,700 million USD by early 2023 but showed modest recovery, stabilizing around 8,900 million USD toward mid-2025.
Retained Earnings: Retained earnings exhibit consistent growth from 23,360 million USD in early 2020 to approximately 35,549 million USD by mid-2025, signaling accumulation of earnings over time.
Accumulated Other Comprehensive Income (Loss): This item shows persistent negative balances with considerable volatility, with significant worsening around 2021 and some moderate improvement toward mid-2025 but remaining a liability overall.
Shareholders’ Equity: Shareholders' equity increased steadily from 31,693 million USD at the beginning of 2020 to 43,722 million USD by mid-2025, reflecting retained earnings growth outpacing accumulated losses in other comprehensive income.
Noncontrolling Interests: Noncontrolling interests remain modest but trend upwards from absence in early data to around 129 million USD by mid-2025, indicating small but growing external ownership stakes.
Total Equity: Total equity followed the trajectory of shareholders' equity, rising from approximately 31,693 million USD to over 43,851 million USD, demonstrating strengthening equity base despite some fluctuations.
Total Liabilities and Equity: The total of liabilities and equity increased steadily from approximately 82,399 million USD at the start of 2020 to nearly 122,000 million USD by mid-2025, consistent with growth in both liabilities and equity.

Download chart

Elevance Health Inc. (NYSE:ELV)

Balance Sheet: Liabilities and Stockholders’ Equity Quarterly Data

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data